Moreover, SRC may associate with HER receptors (Kim et al., 2005), and previous data in HER2‐overexpressing breast cancer cells indicated that SRC inhibition prevented ERK1/2 activation (Seoane et al., 2010). Here, MAPK3 is linked to breast cancer.